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Brief Definitive Report IL-2 alone or in combination with the adoptive transfer of either lymphocyteactivated killer cells (LAK) or tumor-infiltrating lymphocytes (TIL) has shown efficacy in the treatment of certain human malignancies (1, 2) . However, IL-2-based immunotherapy protocols are associated with considerable systemic toxicity (1, 3) . The pathophysiologic consequences of high dose IL-2 administration in man are variably composed of a "vascular leak syndrome, marked fluid retention and weight gain, decreased systemic vascular resistance, increased cardiac output, hypotension, elevated creatinine, and elevated bilirubin (4) (5) (6) (7) . This constellation of changes is remarkably similar to the alterations seen in septic shock. A series of recent investigations have identified the monocyte/macrophage product, TNF, as an important mediator of toxicity in endotoxemia and Gram-negative sepsis (8, 9) . The clinical similarities between IL-2 toxicity and sepsis suggest a potential role for TNF as a mediator of the toxic effects of IL-2 (3). Evidence to support this hypothesis is that IL-2 induces transcription and translation of TNF in LAK cells and macrophages (10) (11) (12) , as well as recent studies that measure circulating TNF in humans receiving IL-2 alone or IL-2 and LAK (13, 14) .
The present study investigates the role of TNF in IL-2 toxicity by administering high levels ofneutralizing antiTNF antibody concurrently with high dose IL-2 treatment in mice. The effects of TNF antibody on IL-2 toxicity as well as the antitumor efficacy of IL-2 are evaluated.
Materials and Methods
Mice. Female C57BL/6 mice and C3H/HEN mice 12-16 wk old were obtained from the small animals section, Veterinary Resources Branch, NIH, Bethesda, MD.
muTNFAntibody Prefiaration. New Zealand white rabbits 3-4 kg were immunized to recombinant murine TNF=a (rmuTNF) (Genentech, South San Francisco, CA) or to recombinant rat IFN-y (Amgen Corp., Thousand Oaks, CA) and bled in a standard fashion. Sera were passed over a recombinantproteinA column (10 ml bed volume), washed, eluted, and desalted per manufacturer's recommendations (Beckman Instruments, Inc., Fullerton, CA). Column aliquots were screened for TNF antibody as described below and positive aliquots were pooled to obtain the TNF antibody solution used in all experiments.
Characterization of rmuTNFAntibody. The neutralizing activity of the TNF antibody solution was quantitated by serial dilution using the L929 cytolytic assay (15) . The greatest dilution ofantibody solution that led to 100% survival ofL929 cells wasused toquantitate neutralizing activity. IgG concentration ofthe antibody solution was measured by radial immunodiffusion (ICN Immunobiologicals, Irvine, CA).
Pulmonary Metastases Tumor Model. A murine pulmonary metastases model using a weakly immunogenic methylcholanthrene-induced tumor (MCA-106) was used . Tumor preparation and analysis were done as previously described (16) ; metastases were counted in a blinded fashion (17) . By prior convention, ifthere were >250 metastases that lung was scored as >250 as higher numbers oflesions could not be counted (17) . Mice were treated with recombinant human IL-2 (Cetus Corp., Emeryville, CA) 100,000 U i.p. every 8 h or HBSS control.
Statistics . Survival curves were analyzed by the Breslow modification ofthe KruskalWallis test. Metastases number are shown as mean t SEM and compared by the Wilcoxon Rank Sum test corrected for multiple comparisons.
Results and Discussion
The polyvalent antisera to recombinant murine TNF used in all experiments neutralized 5 x 106 U of TNF per milliliter of antibody solution in a standard L929 cytolytic assay. The specificity of the antisera was evaluated by bioassay and immunoblot techniques. The TNF antibody had no neutralizing activity against HL-2 in a CTLL proliferation assay (data not shown). To evaluate the efficacy of the TNF establish an appropriate in vi the experiment of Beutler et al. (8) using polyvalent TNF antibody to protect against a lethal dose of endotoxin. Pretreatment of mice with 5 x 105 U i.p. of neutralizing activity 6 h before challenge with an LDloo dose of endotoxin gave complete protection from death in all mice ; whereas pretreatment with 2.5 x 105 U of neutralizing activity afforded no protection.
To determine the effects of TNF antibody on IL-2 toxicity, mice were injected with 100,000 U i.p. of IL-2 every 8 h and the number of doses ofIL-2 received before death was recorded . C3H/HEN mice receiving control rabbit IgG died reproducibly after receiving 10-12 doses of IL-2 (mean dose, 11.1). Mice that were injected with varying doses of TNF antibody ranging from 0.5 to 2.0 x 106 U i.p. of neutralizing activity once daily during IL-2 treatment survived significantly more doses of IL-2 than control mice treated with nonspecific antibody (p < 0.005 vs. control for all TNF antibody groups; Fig. I A) . The protective effect ofTNF antibody against IL-2 lethality was observed as a dose-response. Another control using polyvalent rabbit antisera against rat IFN was no different than control rabbit IgG, indicating that the TNF protective effect was not due to administration of a hyperimmune sera (Fig. 1 A) .
TNF antibody afforded a similar protective effect against IL-2 toxicity in C57BL/6 mice with microscopic (3 day) and macroscopic (10 day) pulmonary sarcoma metastases (Fig . 1 B) . The mean dose of IL-2 plus control IgG that resulted in death was 14.5 for mice with 3-d pulmonary metastases and 14 for mice with 10-d pulmonary metastases, but 14/15 mice with 3-d pulmonary metastases and 12/12 mice with 10-d metastases treated with antibody to TNF tolerated 20 doses of IL-2 without mortality (ß < 0.001).
The effect of TNF antibody on the antitumor activity of IL-2 can be evaluated by comparing the treatment response of mice receiving equal doses of IL-2 with or without the TNF antibody. Mice given IL-2 with TNF antibody have significantly fewer metastases than control mice receiving the vehicle (HBSS) alone or HBSS and TNF antibody (p < 0 .001 vs . both HBSS controls in all experiments ; Table I ). TNF antibody-treated mice have aconsistent but not statistically significant increase in pulmonary metastases compared with mice receiving an equal amount of IL-2 with control antibody in three experiments . Whether additional administration of IL-2 made possible by the protective effect ofTNF antibody improves the therapeutic response can be evaluated by comps mice receiving equitoxic amounts of IL-2 with or without the TNF antibody. The maximal amount of IL-2 tolerated by mice receiving control antibody was given in the experiments shown in Table I , as evidenced by the occurrence of IL-2 treatment deaths . One subgroup of mice given TNF antibody received additional IL-2 until obvious toxicity and imminent mortality was observed, and these mice can be considered to have received equitoxic doses of IL-2 compared with mice given control antibody and IL-2. In the 3-d pulmonary metastases model, IL-2 alone is so effective, 96 and 89% reduction in metastases number in Exps . I and 2, respectively (Table I) , that it is difficult to demonstrate an improved therapeutic effect with additional doses of IL-2 made possible by TNF antibody in this micrometastases model .
In mice given 3 x 106 MCA-106 cells and treated at 10 d after tumor injection with 20 doses of IL-2 plus TNF antibody (Exp. 3) there was a modest but insignificant decrease in pulmonary metastases compared with mice given 12 doses of IL-2 and control antibody (24 vs. 53 metastases, ib = 0.06 ; Table I ). In a similar 10-d metastases experiment in which mice were injected with 106 MCA-106, an improved response after additional IL-2 administration was more apparent. In this experiment control mice given HBSS with control or TNF antibody had >250 metastases (Fig . 2, A  and B) . Mice given 12 doses of IL-2 and daily control antibody had an IL-2 treatment mortality of 25% (3112) and the remaining nine mice had a mean of 230 pulmonary metastases (Fig . 2 G") with TNF antibody had a similar IL-2 treatment reponse (mean number of metastases, 228 ; Fig. 2 D) . A second subgroup ofmice given daily TNF antibody in this experiment tolerated 20 doses of IL-2 without treatment mortality and the number of metatases was 173 (p < 0 .02 vs. IL-2 plus control antibody). Although the apparent de- crease in tumor number is relatively small, the actual decrease in tumor burden by the additional eight doses of IL-2 made possible by concurrent TNF antibody is greater as the size of the metastases in this group also appears to be substantially decreased (Fig. 2 E) . The results in both non-tumor-bearing and tumor-bearing mice indicate that endogenous TNF production is a mediator of systemic IL-2 toxicity. Mice treated with TNF antibody tolerate between 30 and 60% more IL-2 than control mice before IL-2 death. Since TNF antibody-treated mice eventually die secondary to IL-2 toxicity despite continued antibody injection, then either other mechanisms of IL-2 toxicity exist or inadequate amounts of TNF antibody were given. The former explanation is most likely. IL-2 administration induces other potentially toxic host factors such as lymphotoxin, IFN-y, and IL-1 (10, 11, 17) , as well as having pleotropic immune effects that would be unaffected by TNF antibody.
Passive immunization against TNF may dissociate the toxic effects of IL-2 from the antineoplastic activity of IL-2 . In consecutive experiments where equal doses of IL-2 were given, the addition of TNF antibody did not significantly alter the antineoplastic effect of IL-2 . Lessening IL-2 toxicity while maintaining treatment efficacy is a potentially clinically relevant observation. In one experiment additional IL-2 administration made possible by TNF antibody effected a modest decrease in tumor number but a dramatic decrease in tumor burden compared with equitoxic doses of IL-2 plus control antibody (Fig. 2) . Further experiments using different tumor histologies at different anatomic sites are necessary to delineate the utility of TNF antisera as a strategy to improve the therapeutic index in IL-2 immunotherapy.
Summary
Passive immunization against TNF allowed non-tumor-bearing C3H/HEN mice and tumor-bearing C57BL/6 mice to tolerate significantly more doses of IL-2 before death (p < 0.005 and p < 0.001, respectively) . The antitumor effect of IL-2 against both 3-d and 10-d pulmonary metastases was maintained in mice treated concurrently with neutralizing antibodies to TNF . In one experiment with 10-d pulmonary metastases, increased administration of IL-2 made possible by passive immunization against TNF significantly improved the antitumor response compared to equitoxic doses of IL-2 and control antibody. The results indicate that TNF is a mediator of IL-2 toxicity but contributes minimally to the antitumor effects of IL-2 . Strategies to inhibit TNF may improve the therapeutic index of IL-2 as a neoplastic agent.
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